Safety and Efficacy of CD33-Targeted CAR-NK Cell Therapy for Relapsed/Refractory AML
Author Information
Author(s): Huang Ruihao, Wang Xiaoqi, Yan Hongju, Tan Xu, Ma Yingying, Wang Maihong, Han Xiao, Liu Jia, Gao Li, Gao Lei, Jing Guangjun, Zhang Cheng, Wen Qin, Zhang Xi
Primary Institution: Xinqiao Hospital of Army Medical University
Hypothesis
Can CD33-targeted CAR-NK cell therapy improve outcomes for patients with relapsed/refractory acute myeloid leukemia?
Conclusion
CD33 CAR-NK cells demonstrated primary efficacy and safety for patients with relapsed/refractory AML.
Supporting Evidence
- Six of ten patients achieved minimal residual disease-negative complete remission by day 28.
- No grade 3-4 adverse events were observed, except for manageable bone marrow suppression.
- The median number of prior treatments for patients was five.
Takeaway
This study tested a new treatment for a type of blood cancer using special immune cells that target cancer cells while being safer than previous methods.
Methodology
The study involved a phase I trial with 10 patients receiving CD33 CAR-NK cell infusions after a preconditioning regimen.
Potential Biases
Potential biases may arise from the small sample size and lack of a control group.
Limitations
The study had a small sample size and a short follow-up period.
Participant Demographics
Patients aged 18-65 with relapsed/refractory AML, median age 42.5 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website